Abstract
Antisense long noncoding RNAs (lncRNAs) play important roles in regulating the expression of coding genes in post-transcriptional level. However, detailed expression profile of lncRNAs and functions of antisense lncRNAs in bladder cancer remains unclear. To investigate regulation of lncRNAs in bladder cancer and demonstrate their functions, we performed lncRNAs microarray analysis in 3 paired bladder cancer tissues. Further molecular assays were conducted to determine the potential role of identified antisense lncRNA MDC1-AS. As a result, a series of lncRNAs were differentially expressed in bladder cancer tissues in microarray screen. In a larger size of samples validation, we found that the expression levels of MDC1-AS and MDC1 was down-regulated in bladder cancer. After over-expression of MDC1-AS, increased levels of MDC1 were observed in bladder cancer cells. We also found a remarkably inhibitory role of antisense lncRNA MDC1-AS on malignant cell behaviors in bladder cancer cells EJ and T24. Subsequently, knockdown of MDC1 revealed that suppressing role of MDC1-AS was attributed to up-regulation of MDC1. In summary, we have identified a novel antisense lncRNA MDC1-AS, which may participate in bladder cancer through up-regulation of its antisense tumor-suppressing gene MDC1. Further studies should be conducted to demonstrate detailed mechanism of our findings.
Highlights
Bladder cancer is a common malignancy in urinary system
Following the verification of inhibitory role of Mediator of DNA damage checkpoint protein 1 (MDC1)-AS on bladder cancer cells viability, we further investigate whether this long noncoding RNAs (lncRNAs) participant in cells migration and invasion
In the repeated CCK-8 assay, we found that inhibitory role of MDC1-AS on bladder cancer cells proliferation was weakened with co-transfection of siMDC1
Summary
Bladder cancer is a common malignancy in urinary system. According to data of Global Cancer Statistics, about 440,000 new cases of bladder cancer are diagnosed while 130,000 patients died from it around the world every year. In China, bladder cancer has the highest incidence in all urinary system tumors and the mortality increased significantly during the past decades [1]. The high recurrence rate of non-invasive bladder cancer [2] and the evident aggressive performance of invasive bladder cancer are the main threaten to patient life. The effective therapy for bladder cancer is still deficient because the detailed mechanism underlying bladder cancer is unclear. Intensive study into the molecular mechanism will promote clinical treatment of bladder cancer
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
